Mol Genet Genomics 291, 16391646 (2016)
The regulatory read Randomized, double-blind, placebo-controlled Co-primary endpoints: PASI 75 + sPGA 0/1 at Week 16 (standard registration bar) Protocol aligned with both FDA and EMA de-risks a dual US/EU submission path Accrual continues toward ~705 total participants Read this as a milestone, not a signal
Devi KP, Rajavel T, Nabavi SF, et al
Procurement Considerations When selecting a BPC-157 + TB-500 supplier, laboratories typically evaluate peptide purity, analytical verification, Certificate of Analysis availability, manufacturing consistency, production scalability, OEM capability, batch traceability, and long-term supply reliability
adding GIP agonism appears to further enhance the appetite and metabolic effect